Serveur d'exploration Tocilizumab - Exploration (Accueil)

Index « Keywords » - entrée « Antirheumatic Agents (adverse effects) »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Antirheumatic Agents (administration & dosage) < Antirheumatic Agents (adverse effects) < Antirheumatic Agents (blood)  Facettes :

List of bibliographic references indexed by Antirheumatic Agents (adverse effects)

Number of relevant bibliographic references: 317.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
000571 (2020) Seong-Kyu Kim ; Sang Gyu Kwak [Corée du Sud] ; Jung-Yoon ChoeAssociation between biologic disease modifying anti-rheumatic drugs and incident hypertension in patients with rheumatoid arthritis: Results from prospective nationwide KOBIO Registry.
000653 (2019) Lianne Kearsley-Fleet [Royaume-Uni] ; Sunil Sampath [Royaume-Uni] ; Liza J. Mccann [Royaume-Uni] ; Eileen Baildam [Royaume-Uni] ; Michael W. Beresford [Royaume-Uni] ; Rebecca Davies [Royaume-Uni] ; Diederik De Cock [Royaume-Uni] ; Helen E. Foster [Royaume-Uni] ; Taunton R. Southwood [Royaume-Uni] ; Wendy Thomson [Royaume-Uni] ; Kimme L. Hyrich [Royaume-Uni]Use and effectiveness of rituximab in children and young people with juvenile idiopathic arthritis in a cohort study in the United Kingdom.
000695 (2019) Michitaro Hayakawa [Japon] ; Keisuke Izumi [Japon] ; Misako Higashida-Konishi [Japon] ; Mari Ushikubo [Japon] ; Masako Tsukamoto [Japon] ; Kumiko Akiya [Japon] ; Kazuhiro Araki [Japon] ; Hisaji Oshima [Japon]Tocilizumab-induced psoriasis-like eruption resolved by shortening the dose interval in a patient with rheumatoid arthritis: a case-based review.
000704 (2019) Kentaro Chino [Japon] ; Tsuneo Kondo [Japon] ; Ryota Sakai [Japon] ; Shuntaro Saito [Japon] ; Yusuke Okada [Japon] ; Akiko Shibata [Japon] ; Takahiko Kurasawa [Japon] ; Ayumi Okuyama [Japon] ; Hirofumi Takei [Japon] ; Koichi Amano [Japon]Tocilizumab monotherapy for polymyalgia rheumatica: A prospective, single-center, open-label study.
000706 (2019) Martina Biggioggero [Oman] ; Chiara Crotti [Italie] ; Andrea Becciolini [Oman] ; Ennio Giulio Favalli [Oman]Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection.
000723 (2019) Fenglong Xie [Royaume-Uni] ; Huifeng Yun [Royaume-Uni] ; Emily B. Levitan [Royaume-Uni] ; Paul Muntner [Royaume-Uni] ; Jeffrey R. Curtis [Royaume-Uni]Tocilizumab and the Risk of Cardiovascular Disease: Direct Comparison Among Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Patients.
000768 (2019) Kosuke Ebina [Japon] ; Akira Miyama [Japon] ; Hideki Tsuboi [Japon] ; Shoichi Kaneshiro [Japon] ; Masataka Nishikawa [Japon] ; Hajime Owaki [Japon] ; Shigeyoshi Tsuji [Japon] ; Makoto Hirao [Japon] ; Yuki Etani [Japon] ; Atsushi Goshima [Japon] ; Jun Hashimoto [Japon] ; Hideki Yoshikawa [Japon]The add-on effectiveness and safety of iguratimod in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab.
000818 (2019) C. Turesson [Suède] ; O. Börjesson [Suède] ; K. Larsson [Suède] ; A J Mohammad [Suède] ; A. Knight [Suède]Swedish Society of Rheumatology 2018 guidelines for investigation, treatment, and follow-up of giant cell arteritis.
000870 (2019) Ching-Tsai Lin [Taïwan] ; Wen-Nan Huang [Taïwan] ; Chia-Wei Hsieh [Taïwan] ; Yi-Ming Chen [Taïwan] ; Der-Yuan Chen [Taïwan] ; Tsu-Yi Hsieh [Taïwan] ; Yi-Hsing Chen [Taïwan]Safety and effectiveness of tocilizumab in treating patients with rheumatoid arthritis - A three-year study in Taiwan.
000880 (2019) Ajinkya Pawar [États-Unis] ; Rishi J. Desai [États-Unis] ; Daniel H. Solomon [États-Unis] ; Adrian J. Santiago Ortiz [États-Unis] ; Sara Gale [États-Unis] ; Min Bao [États-Unis] ; Khaled Sarsour [États-Unis] ; Sebastian Schneeweiss [États-Unis] ; Seoyoung C. Kim [États-Unis]Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
000881 (2019) Kathrine Lederballe Gr N [Oman] ; Elizabeth V. Arkema [Suède] ; Bente Glintborg [Danemark] ; Frank Mehnert [Danemark] ; Mikkel Stergaard [Danemark] ; Lene Dreyer [Danemark] ; Mette N Rgaard [Danemark] ; Niels Steen Krogh [Danemark] ; Johan Askling [Suède] ; Merete Lund Hetland [Danemark]Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden.
000888 (2019) Michael D. George ; Joshua F. Baker ; Kevin Winthrop [États-Unis] ; Evo Alemao ; Lang Chen ; Sean Connolly ; Jesse Y. Hsu ; Teresa A. Simon ; Qufei Wu ; Fenglong Xie ; Shuo Yang ; Jeffrey R. CurtisRisk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty: A Cohort Study.
000892 (2019) Kenji Oku [Japon] ; Tatsuya Atsumi [Japon]Rheumatology practice in Japan: challenges and opportunities.
000894 (2019) Emma L. Simpson [Royaume-Uni] ; Shijie Ren [Royaume-Uni] ; Emma S. Hock [Royaume-Uni] ; John W. Stevens [Royaume-Uni] ; Aymeric Binard [France] ; Yves-Marie Pers [France] ; Rachel Archer [Royaume-Uni] ; Suzy Paisley [Royaume-Uni] ; Matthew D. Stevenson [Royaume-Uni] ; Chloé Herpin [France] ; Salah Ghabri [France]Rheumatoid arthritis treated with 6-months of first-line biologic or biosimilar therapy: an updated systematic review and network meta-analysis.
000899 (2019) Ryuki Sakaguchi [Japon] ; Keita Fujikawa [Japon] ; Momoko Okamoto [Japon] ; Emi Matsuo [Japon] ; Kohei Matsumoto [Japon] ; Tomohisa Uchida [Japon] ; Kawashiri Shin-Ya [Japon] ; Masahiro Nakashima [Japon] ; Akinari Mizokami [Japon] ; Atsushi Kawakami [Japon]Rheumatoid Arthritis Complicated with Nasal Septum Perforation Due to Methotrexate-associated Lymphoproliferative Disorder
000902 (2019) Shunsuke Mori [Japon] ; Tamami Yoshitama [Japon] ; Yasuyo Abe [Japon] ; Toshihiko Hidaka [Japon] ; Naoyuki Hirakata [Japon] ; Kiyoshi Aoyagi [Japon] ; Yukitaka Ueki [Japon]Retention of tocilizumab with and without methotrexate during maintenance therapy for rheumatoid arthritis: the ACTRA-RI cohort study.
000930 (2019) Durga Prasanna Misra [Inde] ; Anupam Wakhlu [Inde] ; Vikas Agarwal [Inde] ; Debashish Danda [Inde]Recent advances in the management of Takayasu arteritis.
000950 (2019) Kenan Barut [Turquie] ; Amra Adrovic [Turquie] ; Sezgin Sahin [Turquie] ; Gurkan Tarcin [Turquie] ; Gulberk Tahaoglu [Turquie] ; Oya Koker [Turquie] ; Mehmet Yildiz [Turquie] ; Ozgur Kasapcopur [Turquie]Prognosis, complications and treatment response in systemic juvenile idiopathic arthritis patients: A single-center experience.
000B11 (2019) Atsushi Ogata [Japon] ; Yoshiya Tanaka [Japon] ; Tomonori Ishii [Japon] ; Motohide Kaneko [Japon] ; Hiroko Miwa [Japon] ; Shino Ohsawa [Japon] ; Reiji Yamakawa [Japon]Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: Results from the open-label extension of the SHINOBI study.
000B13 (2019) Vivian P. Bykerk [États-Unis] ; Andrew J K. Östör [Australie] ; José Alvaro-Gracia [Espagne] ; Karel Pavelka [République tchèque] ; José Andrés Román Ivorra [Espagne] ; Michael T. Nurmohamed [Pays-Bas] ; Yves Luder [Suisse] ; Paris N M. Sidiropoulos [États-Unis] ; Jenny Devenport [États-Unis] ; Jean Sibilia [France]Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice.
000B44 (2019) Navita L. Mallalieu [États-Unis] ; Sunethra Wimalasundera [Royaume-Uni] ; Joy C. Hsu [États-Unis] ; Wendy Douglass [Royaume-Uni] ; Chris Wells [Royaume-Uni] ; Inmaculada Calvo Penades [Espagne] ; Ruben Cuttica [Argentine] ; Hans-Iko Huppertz [Allemagne] ; Rik Joos [Belgique] ; Yukiko Kimura [États-Unis] ; Diana Milojevic [États-Unis] ; Margalit Rosenkranz [États-Unis] ; Kenneth Schikler [États-Unis] ; Tamas Constantin [Hongrie] ; Carine Wouters [Belgique]Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i -k "Antirheumatic Agents (adverse effects)" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i  \
                -Sk "Antirheumatic Agents (adverse effects)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Antirheumatic Agents (adverse effects)
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021